{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:06:48Z","timestamp":1794956808278,"version":"4.9.1"},"reference-count":178,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016112","name":"Universit\u00e0 degli Studi di Foggia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.biopha.2025.118199","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T23:50:07Z","timestamp":1747957807000},"page":"118199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Can ketamine therapy overcome treatment-resistant depression in Alzheimer's disease and older adults? Preclinical and clinical evidence"],"prefix":"10.1016","volume":"188","author":[{"given":"Altamura","family":"Mario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leccisotti","family":"Ivana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moretti Maria","family":"Claudia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bellomo","family":"Antonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panza","family":"Francesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassano","family":"Tommaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lozupone","family":"Madia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118199_bib1","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.neurobiolaging.2009.05.002","article-title":"Reduced hippocampal glutamate in Alzheimer disease","volume":"32","author":"Rupsingh","year":"2011","journal-title":"Neurobiol. Aging"},{"issue":"6","key":"10.1016\/j.biopha.2025.118199_bib2","doi-asserted-by":"crossref","first-page":"1121.e1","DOI":"10.1016\/j.neurobiolaging.2011.09.021","article-title":"Glutamatergic alterations and mitochondrial impairment in a murine model of Alzheimer disease","volume":"33","author":"Cassano","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.biopha.2025.118199_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.890855","article-title":"Effects of ultramicronized palmitoylethanolamide on mitochondrial bioenergetics, cerebral metabolism, and glutamatergic transmission: an integrated approach in a triple transgenic mouse model of Alzheimer's disease","volume":"14","author":"Bellanti","year":"2022","journal-title":"Front Aging Neurosci."},{"issue":"23","key":"10.1016\/j.biopha.2025.118199_bib4","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.3390\/molecules29235744","article-title":"Glutamate: Molecular mechanisms and signaling pathway in Alzheimer\u2019s disease, a potential therapeutic target","volume":"29","author":"Puranik","year":"2024","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.biopha.2025.118199_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13195-024-01661-y","article-title":"Exome sequencing reveals a rare damaging variant in GRIN2C in familial late-onset Alzheimer's disease","volume":"17","author":"Rubino","year":"2025","journal-title":"Alzheimers Res Ther."},{"issue":"4","key":"10.1016\/j.biopha.2025.118199_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095413","article-title":"Overrepresentation of glutamate signaling in Alzheimer's disease: network-based pathway enrichment using meta-analysis of genome-wide association studies","volume":"9","author":"P\u00e9rez-Palma","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2025.118199_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3233\/JAD-148003","article-title":"Neuropathology of depression in Alzheimer's disease: current knowledge and the potential for new treatments","volume":"44","author":"Khundakar","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2025.118199_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fnins.2019.00043","article-title":"The role of NMDA receptors in Alzheimer's disease","volume":"13","author":"Liu","year":"2019","journal-title":"Front Neurosci."},{"key":"10.1016\/j.biopha.2025.118199_bib9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1176\/ajp.146.5.577","article-title":"Overview of depression and psychosis in Alzheimer\u2019s disease","volume":"146","author":"Wragg","year":"1989","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118199_bib10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.4140\/TCP.n.2014.254","article-title":"Antidepressants for depression in patients with dementia: a review of the literature","volume":"29","author":"Leong","year":"2014","journal-title":"Consult Pharm."},{"key":"10.1016\/j.biopha.2025.118199_bib11","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/archpsyc.63.5.530","article-title":"Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis","volume":"63","author":"Ownby","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118199_bib12","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3233\/JAD-161247","article-title":"Efficacy of antidepressants for depression in Alzheimer\u2019s disease: systematic review and meta-analysis","volume":"58","author":"Orgeta","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2025.118199_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.638651","article-title":"Depression in Alzheimer's disease: a Delphi consensus on etiology, risk factors, and clinical management","volume":"12","author":"Ag\u00fcera-Ortiz","year":"2021","journal-title":"Front Psychiatry"},{"issue":"3","key":"10.1016\/j.biopha.2025.118199_bib14","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.biopha.2025.118199_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neubiorev.2019.04.002","article-title":"Depression in neurodegenerative diseases: common mechanisms and current treatment options","volume":"102","author":"Galts","year":"2019","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.biopha.2025.118199_bib16","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3389\/fphar.2019.01067","article-title":"Pharmacological treatment of depression in Alzheimer's disease: a challenging task","volume":"10","author":"Cassano","year":"2019","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2025.118199_bib17","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1017\/S003329172200397X","article-title":"Antidepressant medications in dementia: evidence and potential mechanisms of treatment-resistance","volume":"53","author":"Costello","year":"2023","journal-title":"Psychol. Med"},{"key":"10.1016\/j.biopha.2025.118199_bib18","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/gps.1763","article-title":"Possible therapeutic implication of A beta disturbances in depression","volume":"22","author":"Pomara","year":"2007","journal-title":"Int J. Geriatr. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118199_bib19","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/00019442-200305000-00011","article-title":"Partial response as a predictor of outcome in geriatric depression","volume":"11","author":"Steffens","year":"2003","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118199_bib20","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1176\/appi.ajp.2011.10081165","article-title":"A systematic review of treatments for refractory depression in older people","volume":"168","author":"Cooper","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"Pt A","key":"10.1016\/j.biopha.2025.118199_bib21","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jad.2020.11.042","article-title":"Cause-specific life years lost in individuals with treatment-resistant depression: a Danish nationwide register-based cohort study","volume":"280","author":"Madsen","year":"2021","journal-title":"J. Affect Disord."},{"issue":"12","key":"10.1016\/j.biopha.2025.118199_bib22","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.4088\/JCP.10r06531","article-title":"Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials","volume":"72","author":"Tedeschini","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.biopha.2025.118199_bib23","doi-asserted-by":"crossref","first-page":"688","DOI":"10.4088\/JCP.v67n0501","article-title":"Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression","volume":"67","author":"Dunner","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118199_bib24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1001\/archneur.63.3.435","article-title":"Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study","volume":"63","author":"Geda","year":"2006","journal-title":"Arch. Neurol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118199_bib25","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/gps.4406","article-title":"Depressive symptoms increase the risk of progression to dementia in subjects with mild cognitive impairment: systematic review and meta-analysis","volume":"31","author":"Mourao","year":"2016","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118199_bib26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3233\/JAD-150679","article-title":"Depressive symptoms and small hippocampal volume accelerate the progression to dementia from mild cognitive impairment","volume":"49","author":"Chung","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2025.118199_bib27","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.biopsych.2011.12.024","article-title":"Depressive symptoms in mild cognitive impairment predict greater atrophy in Alzheimer's disease-related regions","volume":"71","author":"Lee","year":"2012","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.biopha.2025.118199_bib28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/JGP.0b013e3181b0fa13","article-title":"Late-life depression, mild cognitive impairment, and dementia: possible continuum?","volume":"18","author":"Panza","year":"2010","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"6","key":"10.1016\/j.biopha.2025.118199_bib29","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/YCO.0b013e32834bb9d4","article-title":"Depression in dementia: epidemiology, mechanisms, and treatment","volume":"24","author":"Enache","year":"2011","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118199_bib30","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jad.2020.05.150","article-title":"Treatment-resistant depression enhances risks of dementia and Alzheimer\u2019s disease: a nationwide longitudinal study","volume":"274","author":"Chan","year":"2020","journal-title":"J. Affect Disord."},{"key":"10.1016\/j.biopha.2025.118199_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/bs.pbr.2023.02.004","article-title":"Treatment resistant depression in elderly","volume":"281","author":"Wang","year":"2023","journal-title":"Prog. Brain Res."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2025.118199_bib32","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.brainresrev.2011.04.003","article-title":"Late-life depression and Alzheimer's disease: the glutamatergic system inside of this mirror relationship","volume":"67","author":"Frisardi","year":"2011","journal-title":"Brain Res. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2025.118199_bib33","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3390\/nu14050917","article-title":"Emerging evidence for the widespread role of glutamatergic dysfunction in neuropsychiatric diseases","volume":"14","author":"McGrath","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2025.118199_bib34","article-title":"The role of glutamate in a multifactorial scenario of Alzheimer\u2019s disease associated with depression and poor sleep","volume":"305","author":"Ruela","year":"2021","journal-title":"Psychiatry Res"},{"issue":"5","key":"10.1016\/j.biopha.2025.118199_bib35","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2174\/1570159X12666140619204251","article-title":"The role of ketamine in treatment-resistant depression: a systematic review","volume":"12","author":"Serafini","year":"2014","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.biopha.2025.118199_bib36","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.2147\/NDT.S117146","article-title":"Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies","volume":"12","author":"Han","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"6","key":"10.1016\/j.biopha.2025.118199_bib37","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1192\/bjp.2023.79","article-title":"Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial","volume":"223","author":"Loo","year":"2023","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118199_bib38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118199_bib39","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00406-020-01110-5","article-title":"Intravenous arketamine for treatment-resistant depression: open-label pilot study","volume":"271","author":"Leal","year":"2021","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"10","key":"10.1016\/j.biopha.2025.118199_bib40","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3390\/biomedicines12102283","article-title":"Ketamine, esketamine, and arketamine: their mechanisms of action and applications in the treatment of depression and alleviation of depressive symptoms","volume":"12","author":"Kawczak","year":"2024","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.biopha.2025.118199_bib41","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/14656566.2018.1471136","article-title":"Pharmacotherapy for the treatment of depression in patients with Alzheimer's disease: a treatment-resistant depressive disorder","volume":"19","author":"Lozupone","year":"2018","journal-title":"Expert Opin. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2025.118199_bib42","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/YIC.0000000000000334","article-title":"Use of subcutaneous ketamine to rapidly improve severe treatment-resistant depression in a patient with Alzheimer's disease","volume":"36","author":"Rocha","year":"2021","journal-title":"Int Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118199_bib43","article-title":"Therapeutic potential of intravenous ketamine in early-onset dementia: a case report","volume":"16","author":"Tadros","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.biopha.2025.118199_bib44","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13024-021-00424-9","article-title":"New approaches to symptomatic treatments for Alzheimer\u2019s disease","volume":"16","author":"Cummings","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.biopha.2025.118199_bib45","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/NDT.S198774","article-title":"Management of treatment-resistant depression: challenges and strategies","volume":"16","author":"Voineskos","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"2","key":"10.1016\/j.biopha.2025.118199_bib46","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/JGP.0b013e31816029ec","article-title":"Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression","volume":"16","author":"Rapp","year":"2008","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"4","key":"10.1016\/j.biopha.2025.118199_bib47","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ana.22100","article-title":"Amyloid and tau proteins in cortical brain biopsy and Alzheimer\u2019s disease","volume":"68","author":"Leinonen","year":"2010","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118199_bib48","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/gps.4409","article-title":"High amyloid-\u03b2 deposition related to depressive symptoms in older individuals with normal cognition: a pilot study","volume":"31","author":"Yasuno","year":"2016","journal-title":"Int J. Geriatr. Psychiatry"},{"issue":"8","key":"10.1016\/j.biopha.2025.118199_bib49","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.27248","article-title":"Change in depressive symptoms and longitudinal regional amyloid accumulation in unimpaired older adults","volume":"7","author":"Munro","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.biopha.2025.118199_bib50","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13550-017-0273-4","article-title":"Beta-amyloid deposition in patients with major depressive disorder with differing levels of treatment resistance: a pilot study","volume":"7","author":"Li","year":"2017","journal-title":"EJNMMI Res"},{"issue":"16","key":"10.1016\/j.biopha.2025.118199_bib51","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1017\/S0033291721001070","article-title":"Global cognitive dysfunction and \u03b2-amyloid neuropathology in late-life and treatment-resistant major depression","volume":"52","author":"Li","year":"2022","journal-title":"Psychol. Med"},{"issue":"12","key":"10.1016\/j.biopha.2025.118199_bib52","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.3390\/biomedicines12122747","article-title":"Exploring the complex relationship between antidepressants, depression and neurocognitive disorders","volume":"12","author":"Nea\u021bu","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.biopha.2025.118199_bib53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1176\/jnp.13.1.5","article-title":"Role of serotonin in the behavioral and psychological symptoms of dementia","volume":"13","author":"Lanct\u00f4t","year":"2001","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118199_bib54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13195-014-0090-1","article-title":"The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer\u2019s disease","volume":"7","author":"Vermeiren","year":"2015","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.biopha.2025.118199_bib55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/bs.pbr.2021.02.003","article-title":"Anatomical and neurochemical organization of the serotonergic system in the mammalian brain and in particular the involvement of the dorsal raphe nucleus in relation to neurological diseases","volume":"261","author":"Steinbusch","year":"2021","journal-title":": Di Giovanni G, De. Deurwaerdere P, Ed. Prog. Brain Res"},{"issue":"6","key":"10.1016\/j.biopha.2025.118199_bib56","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1046\/j.0305-1846.2000.00291.x","article-title":"The evolution of Alzheimer\u2019s disease-related cytoskeletal pathology in the human raphe nuclei","volume":"26","author":"R\u00fcb","year":"2000","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118199_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0197-4580(02)00057-X","article-title":"HC. Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis","volume":"24","author":"Zarow","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.biopha.2025.118199_bib58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.nbd.2017.05.007","article-title":"Molecular imaging of serotonin degeneration in mild cognitive impairment","volume":"105","author":"Smith","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biopha.2025.118199_bib59","article-title":"Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer\u2019s disease pathology: an 123I-FP-CIT SPECT study","volume":"25","author":"van der Zande","year":"2019","journal-title":"Neuroimage Clin."},{"issue":"1","key":"10.1016\/j.biopha.2025.118199_bib60","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.neuron.2009.12.003","article-title":"5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants","volume":"65","author":"Richardson-Jones","year":"2010","journal-title":"Neuron"},{"issue":"7","key":"10.1016\/j.biopha.2025.118199_bib61","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/brain\/awp069","article-title":"Increased binding to 5-HT1A and 5-HT2A receptors is associated with large vessel infarction and relative preservation of cognition","volume":"132","author":"Elliott","year":"2009","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.biopha.2025.118199_bib62","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1093\/brain\/awab111","article-title":"The role of noradrenaline in cognition and cognitive disorders","volume":"144","author":"Holland","year":"2021","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.biopha.2025.118199_bib63","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1093\/brain\/awz193","article-title":"Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases","volume":"142","author":"Betts","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2025.118199_bib64","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40478-017-0411-2","article-title":"Locus coeruleus cellular and molecular pathology during the progression of Alzheimer\u2019s disease","volume":"5","author":"Kelly","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.biopha.2025.118199_bib65","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.neuropsychologia.2017.07.003","article-title":"M. The anatomy of apathy: a neurocognitive framework for amotivated behaviour","volume":"118","author":"Le Heron","year":"2018","journal-title":"Neuropsychologia"},{"issue":"8","key":"10.1016\/j.biopha.2025.118199_bib66","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41583-018-0029-9","article-title":"Neuroscience of apathy and anhedonia: a transdiagnostic approach","volume":"19","author":"Husain","year":"2018","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.biopha.2025.118199_bib67","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.phrs.2018.01.016","article-title":"The role of dopaminergic midbrain in Alzheimer\u2019s disease: translating basic science into clinical practice","volume":"130","author":"D\u2019Amelio","year":"2018","journal-title":"Pharm. Res"},{"key":"10.1016\/j.biopha.2025.118199_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.1032224","article-title":"BDNF receptor TrkB as the mediator of the antidepressant drug action","volume":"15","author":"Casarotto","year":"2022","journal-title":"Front Mol. Neurosci."},{"issue":"5","key":"10.1016\/j.biopha.2025.118199_bib69","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.cell.2021.01.034","article-title":"Antidepressant drugs act by directly binding to TRKB neurotrophin receptors","volume":"184","author":"Casarotto","year":"2021","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.biopha.2025.118199_bib70","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.biopsych.2007.09.019","article-title":"Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy","volume":"63","author":"Adachi","year":"2008","journal-title":"Biol. Psychiatry"},{"issue":"19","key":"10.1016\/j.biopha.2025.118199_bib71","doi-asserted-by":"crossref","first-page":"14810","DOI":"10.3390\/ijms241914810","article-title":"Brain-derived neurotrophic factor (BDNF) as a predictor of treatment response in major depressive disorder (MDD): a systematic review","volume":"24","author":"Zelada","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2025.118199_bib72","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrneurol.2009.54","article-title":"Brain-derived neurotrophic factor in neurodegenerative diseases","volume":"5","author":"Zuccato","year":"2009","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.biopha.2025.118199_bib73","article-title":"Exploring the role of inflammation in major depressive disorder: beyond the monoamine hypothesis","volume":"17","author":"Pastis","year":"2023","journal-title":"Front Behav. Neurosci."},{"key":"10.1016\/j.biopha.2025.118199_bib74","article-title":"Serum neuroactive metabolites of the tryptophan pathway in patients with acute phase of affective disorders","volume":"15","author":"Li","year":"2024","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.biopha.2025.118199_bib75","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fnins.2014.00012","article-title":"Kynurenines in CNS disease: regulation by inflammatory cytokines","volume":"8","author":"Campbell","year":"2014","journal-title":"Front Neurosci."},{"issue":"4","key":"10.1016\/j.biopha.2025.118199_bib76","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154612","article-title":"Butyrate ameliorates quinolinic acid\u2013induced cognitive decline in obesity models","volume":"133","author":"Ge","year":"2023","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2025.118199_bib77","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s43556-024-00205-y","article-title":"Treatment-resistant depression: molecular mechanisms and management","volume":"5","author":"Kajumba","year":"2024","journal-title":"Mol. Biomed."},{"issue":"1","key":"10.1016\/j.biopha.2025.118199_bib78","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","article-title":"A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers","volume":"70","author":"Raison","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopha.2025.118199_bib79","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jad.2012.10.036","article-title":"Lack of clinical therapeutic benefit of antidepressants is associated with overall activation of the inflammatory system","volume":"148","author":"Carvalho","year":"2013","journal-title":"J. Affect Disord."},{"issue":"5","key":"10.1016\/j.biopha.2025.118199_bib80","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s12264-016-0055-4","article-title":"Inflammatory cytokines and Alzheimer's disease: a review from the perspective of genetic polymorphisms","volume":"32","author":"Su","year":"2016","journal-title":"Neurosci. Bull."},{"issue":"4","key":"10.1016\/j.biopha.2025.118199_bib81","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.it.2020.02.002","article-title":"Neuroimmune connections in aging and neurodegenerative diseases","volume":"41","author":"Scheiblich","year":"2020","journal-title":"Trends Immunol."},{"key":"10.1016\/j.biopha.2025.118199_bib82","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10072-016-2546-5","article-title":"Dysfunction of NMDA receptors in Alzheimer\u2019s disease","volume":"37","author":"Zhang","year":"2016","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.biopha.2025.118199_bib83","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fphar.2013.00146","article-title":"Mechanisms of antidepressant resistance","volume":"4","author":"El-Hage","year":"2013","journal-title":"Front Pharm."},{"issue":"12","key":"10.1016\/j.biopha.2025.118199_bib84","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1038\/s41380-022-01629-0","article-title":"Distinct functions of S-ketamine and R-ketamine in mediating biobehavioral processes of drug dependency: comments on Bonaventura, et al","volume":"28","author":"Shim","year":"2023","journal-title":"Mol. Psychiatry"},{"issue":"7","key":"10.1016\/j.biopha.2025.118199_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28610","article-title":"Depression, an unmet health need in Africa: understanding the promise of ketamine","volume":"10","author":"Millen","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.biopha.2025.118199_bib86","doi-asserted-by":"crossref","first-page":"480","DOI":"10.4103\/psychiatry.IndianJPsychiatry_484_18","article-title":"Efficacy of ketamine therapy in the treatment of depression","volume":"61","author":"Mandal","year":"2019","journal-title":"Indian J. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118199_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102127","article-title":"Ketamine for the treatment of major depression: a systematic review and meta-analysis","volume":"62","author":"Nikolin","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.biopha.2025.118199_bib88","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fnagi.2019.00186","article-title":"Ketamine: a neglected therapy for Alzheimer disease","volume":"11","author":"Smalheiser","year":"2019","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.biopha.2025.118199_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1223145","article-title":"Antidepressant mechanisms of ketamine: a review of actions with relevance to treatment-resistance and neuroprogression","volume":"17","author":"Lullau","year":"2023","journal-title":"Front Neurosci."},{"issue":"4","key":"10.1016\/j.biopha.2025.118199_bib90","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3233\/JAD-160763","article-title":"Role of glutamate and NMDA receptors in Alzheimer's disease","volume":"57","author":"Wang","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2025.118199_bib91","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.REV120.008207","article-title":"The essential elements of Alzheimer's disease","volume":"296","author":"Lei","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118199_bib92","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2010.12.015","article-title":"Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure","volume":"69","author":"Li","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118199_bib93","doi-asserted-by":"crossref","first-page":"6464","DOI":"10.1038\/s41598-018-24933-8","article-title":"Longitudinal two-photon imaging in somatosensory cortex of behaving mice reveals dendritic spine formation enhancement by subchronic administration of low-dose ketamine","volume":"8","author":"Pryazhnikov","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118199_bib94","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1038\/s41380-022-01864-5","article-title":"Ketamine impairs growth cone and synaptogenesis in human GABAergic projection neurons via GSK-3\u03b2 and HDAC6 signaling","volume":"29","author":"Li","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118199_bib95","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2025.118199_bib96","article-title":"Longitudinal effects of ketamine on dendritic architecture in vivo in the mouse medial frontal cortex","volume":"3","author":"Phoumthipphavong","year":"2016","journal-title":"eNeuro"},{"key":"10.1016\/j.biopha.2025.118199_bib97","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.tips.2021.08.003","article-title":"Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics","volume":"42","author":"Aleksandrova","year":"2021","journal-title":"Trends Pharm. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2025.118199_bib98","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.pnpbp.2011.05.010","article-title":"The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder","volume":"35","author":"Jernigan","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.biopha.2025.118199_bib99","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/jnc.13037","article-title":"Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD","volume":"133","author":"Tramutola","year":"2015","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2025.118199_bib100","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.expneurol.2018.09.011","article-title":"Early intrathecal infusion of everolimus restores cognitive function and mood in a murine model of Alzheimer's disease","volume":"311","author":"Cassano","year":"2019","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.biopha.2025.118199_bib101","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12974-020-01915-0","article-title":"Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition","volume":"17","author":"Price","year":"2020","journal-title":"J. Neuroinflamm."},{"issue":"25","key":"10.1016\/j.biopha.2025.118199_bib102","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1523\/JNEUROSCI.2427-21.2022","article-title":"Microglial mTOR activation upregulates Trem2 and enhances \u03b2-amyloid plaque clearance in the Alzheimer\u2019s disease model","volume":"42","author":"Shi","year":"2022","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.biopha.2025.118199_bib103","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3892\/mmr.2013.1600","article-title":"Effects of ketamine on lipopolysaccharide-induced depressive-like behavior and the expression of inflammatory cytokines in the rat prefrontal cortex","volume":"8","author":"Yang","year":"2013","journal-title":"Mol. Med Rep."},{"issue":"4","key":"10.1016\/j.biopha.2025.118199_bib104","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/03009734.2015.1060281","article-title":"The rapid antidepressant effect of ketamine in rats is associated with down-regulation of pro-inflammatory cytokines in the hippocampus","volume":"120","author":"Wang","year":"2015","journal-title":"Ups. J. Med Sci."},{"key":"10.1016\/j.biopha.2025.118199_bib105","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2147\/DDDT.S188636","article-title":"Neuroprotective potential of ketamine prevents developing brain structure impairment and alteration of neurocognitive function induced via isoflurane through the PI3K\/AKT\/GSK-3\u03b2 pathway","volume":"13","author":"Wang","year":"2019","journal-title":"Drug Des. Devel Ther."},{"key":"10.1016\/j.biopha.2025.118199_bib106","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.neulet.2015.05.022","article-title":"Ketamine-mediated alleviation of electroconvulsive shock-induced memory impairment is associated with the regulation of neuroinflammation and soluble amyloid-beta peptide in depressivelike rats","volume":"599","author":"Zhu","year":"2015","journal-title":"Neurosci. Lett."},{"issue":"8","key":"10.1016\/j.biopha.2025.118199_bib107","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1248\/bpb.b17-00131","article-title":"Ketamine alleviates depressive-like behaviors via down-regulating inflammatory cytokines induced by chronic restraint stress in mice","volume":"40","author":"Tan","year":"2017","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.biopha.2025.118199_bib108","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1038\/s41598-017-03590-3","article-title":"Alterations in the inflammatory cytokines and brain-derived neurotrophic factor contribute to depression-like phenotype after spared nerve injury: improvement by ketamine","volume":"7","author":"Xie","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118199_bib109","doi-asserted-by":"crossref","DOI":"10.1017\/S2045796019000751","article-title":"Esketamine for treatment resistant depression: A trick of smoke and mirrors?","volume":"29","author":"Gastaldon","year":"2020","journal-title":"Epidemiol. Psychiatr. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2025.118199_bib110","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.biopha.2025.118199_bib111","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.biopha.2025.118199_bib112","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.biopha.2025.118199_bib113","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3892\/etm.2023.11810","article-title":"Esketamine for treatment\u2011resistant depression: a review of clinical evidence","volume":"25","author":"Vasiliu","year":"2023","journal-title":"Exp. Ther. Med"},{"issue":"3","key":"10.1016\/j.biopha.2025.118199_bib114","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1176\/appi.ajp.20240515","article-title":"Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis","volume":"182","author":"Fountoulakis","year":"2025","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.biopha.2025.118199_bib115","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3390\/neurolint14020025","article-title":"The Possible Application of Ketamine in the Treatment of Depression in Alzheimer's Disease","volume":"14","author":"Mohammad Shehata","year":"2022","journal-title":"Neurol. Int"},{"issue":"2","key":"10.1016\/j.biopha.2025.118199_bib116","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression\u2014TRANSFORM-3","volume":"28","author":"Ochs-Ross","year":"2020","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118199_bib117","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s13670-023-00389-1","article-title":"A new solution to an age-old problem: a review of ketamine and esketamine for treatment-resistant depression in late life","volume":"12","author":"Balaram","year":"2023","journal-title":"Curr. Geri Rep."},{"key":"10.1016\/j.biopha.2025.118199_bib118","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jad.2023.02.151","article-title":"Arketamine as adjunctive therapy for treatment-resistant depression: a placebo-controlled pilot study","volume":"330","author":"Leal","year":"2023","journal-title":"J. Affect Disord."},{"key":"10.1016\/j.biopha.2025.118199_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104762","article-title":"R)-ketamine as prophylactic and therapeutic drug for neurological disorders: beyond depression","volume":"139","author":"Wang","year":"2022","journal-title":"Neurosci. Biobehav Rev."},{"issue":"4","key":"10.1016\/j.biopha.2025.118199_bib120","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol. Psychiatry"},{"issue":"11","key":"10.1016\/j.biopha.2025.118199_bib121","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S2215-0366(22)00317-0","article-title":"Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability","volume":"9","author":"Smith-Apeldoorn","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"10.1016\/j.biopha.2025.118199_bib122","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression","volume":"74","author":"Murrough","year":"2013","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.biopha.2025.118199_bib123","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","article-title":"Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial","volume":"176","author":"Phillips","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.biopha.2025.118199_bib124","first-page":"109","article-title":"Developing an IV ketamine clinic for treatment-resistant depression: a primer","volume":"51","author":"Parikh","year":"2021","journal-title":"Psychopharmacol. Bull."},{"issue":"4","key":"10.1016\/j.biopha.2025.118199_bib125","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3390\/psychoactives3040031","article-title":"Long-term effects of single and repeated ketamine infusions on treatment-resistant depression: a retrospective chart review study","volume":"3","author":"Sakopoulos","year":"2024","journal-title":"Psychoactives"},{"issue":"12","key":"10.1016\/j.biopha.2025.118199_bib126","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jagp.2023.06.016","article-title":"Investigating the effectiveness and tolerability of intranasal esketamine among older adults with treatment-resistant depression (TRD): a post-hoc analysis from the REAL-ESK study group","volume":"31","author":"d'Andrea","year":"2023","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"2","key":"10.1016\/j.biopha.2025.118199_bib127","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression \u2013 TRANSFORM-3","volume":"28","author":"Ochs-Ross","year":"2020","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"11","key":"10.1016\/j.biopha.2025.118199_bib128","article-title":"Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial","volume":"48","author":"Murphy","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopha.2025.118199_bib129","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1395462","article-title":"A narrative review: suicide and suicidal behaviour in older adults","volume":"15","author":"Sadek","year":"2024","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.biopha.2025.118199_bib130","unstructured":"The Institute for Health Metrics and Evaluation. Global Burden of Disease (GBD). 2019. Available from: \u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/mental-health-of-older-adults\u3009 (accessed 25 April 2025)."},{"key":"10.1016\/j.biopha.2025.118199_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2022.103213","article-title":"Suicidality in the geriatric population","volume":"75","author":"Chattun","year":"2022","journal-title":"Asian J. Psychiatr."},{"issue":"11","key":"10.1016\/j.biopha.2025.118199_bib132","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3390\/bs11110142","article-title":"Prevalence of major depressive disorder and correlates of thoughts of death, suicidal behaviour, and death by suicide in the geriatric population \u2013 a general review of literature","volume":"11","author":"Obuobi-Donkor","year":"2021","journal-title":"Behav. Sci."},{"key":"10.1016\/j.biopha.2025.118199_bib133","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.neubiorev.2021.04.011","article-title":"Suicidal behaviour in older age: a systematic review of risk factors associated to suicide attempts and completed suicides","volume":"127","author":"Beghi","year":"2021","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.biopha.2025.118199_bib134","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jad.2025.03.075","article-title":"Risk of suicide in people living with dementia and comorbid mental health conditions: a systematic review and meta-analysis","volume":"379","author":"Medeisyte","year":"2025","journal-title":"J. Affect Disord."},{"key":"10.1016\/j.biopha.2025.118199_bib135","article-title":"Risk of suicide in association with major depressive disorder among patients with dementia: a population-based nested case-control study","volume":"47","author":"Wang","year":"2025","journal-title":"Braz. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.biopha.2025.118199_bib136","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1176\/appi.ajp.2011.10081165","article-title":"A systematic review of treatments for refractory depression in older people","volume":"168","author":"Cooper","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118199_bib137","article-title":"Es)Ketamine for suicidal ideation and behavior: clinical efficacy","volume":"6","author":"Alario","year":"2022","journal-title":"Chronic Stress Thousand Oaks"},{"key":"10.1016\/j.biopha.2025.118199_bib138","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jpsychires.2024.06.020","article-title":"Rapid and long-lasting effects of subcutaneous esketamine on suicidality: an open-label study in patients with treatment-resistant depression","volume":"176","author":"Lopes","year":"2024","journal-title":"J. Psychiatr. Res"},{"key":"10.1016\/j.biopha.2025.118199_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2024.111152","article-title":"Efficacy of single and repeated ketamine administration for suicidal ideation in adults with psychiatric disorders: a meta-analysis","volume":"136","author":"Feng","year":"2025","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.biopha.2025.118199_bib140","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.biopha.2025.118199_bib141","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/JCP.0000000000000441","article-title":"A new perspective on the anti-suicide effects with ketamine treatment: a procognitive effect","volume":"36","author":"Lee","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118199_bib142","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118199_bib143","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jad.2023.04.120","article-title":"A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression","volume":"334","author":"Zheng","year":"2023","journal-title":"J. Affect Disord."},{"key":"10.1016\/j.biopha.2025.118199_bib144","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.biopha.2025.118199_bib145","doi-asserted-by":"crossref","first-page":"7368","DOI":"10.1007\/s12035-019-1613-3","article-title":"S-Ketamine reverses hippocampal dendritic spine deficits in Flinders Sensitive Line rats within 1h of administration","volume":"56","author":"Treccani","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.biopha.2025.118199_bib146","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bbr.2016.09.002","article-title":"Differential regulation of GluA1 expression by ketamine and memantine","volume":"316","author":"Zhang","year":"2017","journal-title":"Behav. Brain Res."},{"issue":"23","key":"10.1016\/j.biopha.2025.118199_bib147","doi-asserted-by":"crossref","first-page":"8649","DOI":"10.1073\/pnas.1323920111","article-title":"Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses","volume":"111","author":"Gideons","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2025.118199_bib148","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1240295","article-title":"Bedside to bench: the outlook for psychedelic research","volume":"14","author":"Acero","year":"2023","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2025.118199_bib149","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.neuro.2022.06.004","article-title":"Ketamine-induced neurotoxicity is mediated through endoplasmic reticulum stress in vitro in STHdhQ7\/Q7 cells","volume":"91","author":"Rigg","year":"2022","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.biopha.2025.118199_bib150","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3233\/JAD-231461","article-title":"Early astrocytic dysfunction is associated with mistuned synapses as well as anxiety and depressive-like behavior in the AppNL-F mouse model of Alzheimer\u2019s disease","volume":"100","author":"Portal","year":"2024","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2025.118199_bib151","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2025.1505908","article-title":"Ketamine does not rescue plaque load or gap detection in the 5XFAD mouse model of Alzheimer\u2019s disease","volume":"17","author":"Wright","year":"2025","journal-title":"Front Aging Neurosci."},{"key":"10.1016\/j.biopha.2025.118199_bib152","doi-asserted-by":"crossref","first-page":"5398","DOI":"10.1002\/alz.14034","article-title":"The ketamine metabolite (2R,6R)-hydroxynorketamine rescues hippocampal mRNA translation, synaptic plasticity and memory in mouse models of Alzheimer\u2019s disease","volume":"20","author":"Ribeiro","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1016\/j.biopha.2025.118199_bib153","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.rpsm.2016.12.001","article-title":"Ketamine associated with electroconvulsive therapy for treatment-resistant depression in the elderly: two case reports","volume":"10","author":"Fortea","year":"2017","journal-title":"Rev. Psiquiatr Salud Ment."},{"issue":"7","key":"10.1016\/j.biopha.2025.118199_bib154","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1017\/S104161021700014X","article-title":"Electroconvulsive therapy with S-ketamine anesthesia for catatonia in coexisting depression and dementia","volume":"29","author":"Litvan","year":"2017","journal-title":"Int Psychogeriatr."},{"issue":"2","key":"10.1016\/j.biopha.2025.118199_bib155","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/JCP.0000000000001006","article-title":"Effects of repeated intravenous ketamine in treatment-resistant geriatric depression: a case series","volume":"39","author":"Bryant","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118199_bib156","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/JCP.0000000000000090","article-title":"Failed response to repeat intravenous ketamine infusions in geriatric patients with major depressive disorder","volume":"34","author":"Szymkowicz","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118199_bib157","doi-asserted-by":"crossref","DOI":"10.4103\/0019-5545.166627","article-title":"Safety and efficacy of ketamine infusion in late onset depression, and conversion to treatment response","volume":"57","author":"Srivastava","year":"2015","journal-title":"Indian J. Psychiatry"},{"issue":"12","key":"10.1016\/j.biopha.2025.118199_bib158","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11920-017-0855-x","article-title":"Use of ketamine in elderly patients with treatment-resistant depression","volume":"19","author":"da Frota Ribeiro","year":"2017","journal-title":"Curr. Psychiatry Rep."},{"issue":"11","key":"10.1016\/j.biopha.2025.118199_bib159","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jagp.2017.06.007","article-title":"Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression","volume":"25","author":"George","year":"2017","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"3","key":"10.1016\/j.biopha.2025.118199_bib160","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jagp.2022.11.013","article-title":"Intravenous ketamine for late-life treatment-resistant depression: a pilot study of tolerability, safety, clinical benefits, and effect on cognition","volume":"31","author":"Oughli","year":"2023","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.biopha.2025.118199_bib161","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/j.jagp.2022.12.175","article-title":"Ketamine infusion therapy for the management of treatment resistant depression in an outpatient geriatric population","volume":"31","author":"Kim","year":"2023","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"9","key":"10.1016\/j.biopha.2025.118199_bib162","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jagp.2020.12.032","article-title":"Safety, tolerability, and real-world effectiveness of intravenous ketamine in older adults with treatment-resistant depression: a case series","volume":"29","author":"Lipsitz","year":"2021","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"5","key":"10.1016\/j.biopha.2025.118199_bib163","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41386-021-01242-9","article-title":"Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial","volume":"47","author":"Lijffijt","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopha.2025.118199_bib164","article-title":"Ketamine treatment for depression in elderly inpatients: an observational case series","volume":"20","author":"R\u00f6mer","year":"2025","journal-title":"J. Affect Disord. Rep."},{"issue":"6","key":"10.1016\/j.biopha.2025.118199_bib165","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.encep.2023.06.010","article-title":"Esketamine for resistant depression in older people with cognitive impairment: a case report","volume":"49","author":"Romani","year":"2023","journal-title":"Encephale"},{"issue":"S1","key":"10.1016\/j.biopha.2025.118199_bib166","doi-asserted-by":"crossref","first-page":"S531","DOI":"10.1192\/j.eurpsy.2024.1103","article-title":"Esketamine for resistant depression in older people with cognitive impairment: a case report","volume":"67","author":"Mazzoni","year":"2024","journal-title":"Eur. Psychiatry"},{"issue":"5","key":"10.1016\/j.biopha.2025.118199_bib167","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jagp.2021.09.014","article-title":"Comparison of long-term efficacy and safety of esketamine nasal spray plus oral antidepressant in younger versus older patients with treatment-resistant depression: post-hoc analysis of SUSTAIN-2","volume":"30","author":"Ochs-Ross","year":"2022","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"6","key":"10.1016\/j.biopha.2025.118199_bib168","doi-asserted-by":"crossref","DOI":"10.1177\/03000605241258473","article-title":"Is there evidence for using ketamine among individuals with dementia?","volume":"52","author":"Kapoor","year":"2024","journal-title":"J. Int Med Res"},{"issue":"3","key":"10.1016\/j.biopha.2025.118199_bib169","doi-asserted-by":"crossref","first-page":"272","DOI":"10.2174\/157015912803217288","article-title":"NMDA neurotransmission dysfunction in behavioral and psychological symptoms of Alzheimer\u2019s disease","volume":"10","author":"Huang","year":"2012","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.biopha.2025.118199_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2024.110999","article-title":"The involvement of neuroinflammation in an animal model of dementia and depression","volume":"133","author":"Zabot","year":"2024","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.biopha.2025.118199_bib171","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer's disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118199_bib172","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1212\/WNL.0000000000002389","article-title":"Brain BDNF expression as a biomarker for cognitive reserve against Alzheimer disease progression","volume":"86","author":"Beeri","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118199_bib173","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","article-title":"Side-effects associated with ketamine use in depression: a systematic review","volume":"5","author":"Short","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.biopha.2025.118199_bib174","doi-asserted-by":"crossref","first-page":"429","DOI":"10.9758\/cpn.22.1034","article-title":"The role of glutamate underlying treatment-resistant depression","volume":"21","author":"Kim","year":"2023","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.biopha.2025.118199_bib175","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2024.4305","article-title":"Depressive symptoms and amyloid pathology","author":"Wiels","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.biopha.2025.118199_bib176","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/14712598.2025.2463963","article-title":"Successes and failures: the latest advances in the clinical development of amyloid-\u03b2-targeting monoclonal antibodies for treating Alzheimer's disease","volume":"25","author":"Panza","year":"2025","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.biopha.2025.118199_bib177","article-title":"The efficacy and safety of esketamine for treatment-resistant depression in older adults: comments on TRANSFORM-3 trial results","author":"Lavretsky","year":"2019","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"4","key":"10.1016\/j.biopha.2025.118199_bib178","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1192\/apt.bp.114.014274","article-title":"Ketamine as a rapid antidepressant: the debate and implications","volume":"22","author":"Ho","year":"2016","journal-title":"BJPsych Adv."}],"updated-by":[{"DOI":"10.1016\/j.biopha.2025.118232","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000}}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225003932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225003932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:47:08Z","timestamp":1758124028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225003932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":178,"alternative-id":["S0753332225003932"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118199","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can ketamine therapy overcome treatment-resistant depression in Alzheimer's disease and older adults? Preclinical and clinical evidence","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118199"}}